Loading
Some tumours change fast and escape drugs quickly; others are stable. A single validated score for how evolvable a tumour is would tell doctors how aggressively to combine treatments.
Copy-number heterogeneity, whole-genome doubling, chromosomal instability signatures, APOBEC activity and ctDNA turnover each predict evolution and relapse in separate studies. The proposal is to define, freeze and prospectively validate one composite evolvability index computed from routine sequencing, analogous to how tumour mutational burden was standardised.
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
Shares Mutational signature, Whole-exome & whole-genome sequencing.
Shares Mutational signature, Tumour mutational burden (TMB).
Shares Tumour heterogeneity and clonal evolution, Biomarkers are not validated or standardised, Comprehensive genomic profiling.
Shares Mutational signature, Tumour mutational burden (TMB), Whole-exome & whole-genome sequencing.
Shares Tumour mutational burden (TMB), Whole-exome & whole-genome sequencing, Biomarkers are not validated or standardised.
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Mutational signature, Tumour mutational burden (TMB), Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.